SG11201510733YA - Rocuronium preparation causing less pain, method for producing the same, and method for reducing and/or alleviating vascular pain to be induced using the same - Google Patents

Rocuronium preparation causing less pain, method for producing the same, and method for reducing and/or alleviating vascular pain to be induced using the same

Info

Publication number
SG11201510733YA
SG11201510733YA SG11201510733YA SG11201510733YA SG11201510733YA SG 11201510733Y A SG11201510733Y A SG 11201510733YA SG 11201510733Y A SG11201510733Y A SG 11201510733YA SG 11201510733Y A SG11201510733Y A SG 11201510733YA SG 11201510733Y A SG11201510733Y A SG 11201510733YA
Authority
SG
Singapore
Prior art keywords
same
pain
induced
producing
reducing
Prior art date
Application number
SG11201510733YA
Other languages
English (en)
Inventor
Keisuke Jinbo
Yutaka Itsuji
Original Assignee
Maruishi Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharma filed Critical Maruishi Pharma
Publication of SG11201510733YA publication Critical patent/SG11201510733YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201510733YA 2013-07-01 2014-06-23 Rocuronium preparation causing less pain, method for producing the same, and method for reducing and/or alleviating vascular pain to be induced using the same SG11201510733YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013138218 2013-07-01
PCT/JP2014/066504 WO2015001995A1 (fr) 2013-07-01 2014-06-23 Préparation de rocuronium avec une douleur vasculaire améliorée, procédé pour la produire et procédé pour réduire et soulager la douleur vasculaire l'employant

Publications (1)

Publication Number Publication Date
SG11201510733YA true SG11201510733YA (en) 2016-01-28

Family

ID=52143574

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510733YA SG11201510733YA (en) 2013-07-01 2014-06-23 Rocuronium preparation causing less pain, method for producing the same, and method for reducing and/or alleviating vascular pain to be induced using the same

Country Status (20)

Country Link
US (1) US10821119B2 (fr)
EP (1) EP3017817B1 (fr)
JP (1) JP5781698B2 (fr)
KR (2) KR102060160B1 (fr)
CN (2) CN105431151A (fr)
AU (1) AU2014285324B2 (fr)
BR (1) BR112015030877B1 (fr)
CA (1) CA2914154C (fr)
DK (1) DK3017817T3 (fr)
ES (1) ES2794529T3 (fr)
HK (1) HK1224183A1 (fr)
IL (1) IL243363B (fr)
MX (1) MX366310B (fr)
NZ (1) NZ714485A (fr)
PH (1) PH12015502850A1 (fr)
PT (1) PT3017817T (fr)
RU (1) RU2680405C2 (fr)
SA (1) SA515370275B1 (fr)
SG (1) SG11201510733YA (fr)
WO (1) WO2015001995A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869876B2 (en) * 2014-06-26 2020-12-22 Maruishi Pharmaceutical Co., Ltd. Rocuronium preparation with improved stability
CN111374942B (zh) * 2018-12-30 2022-09-13 鲁南制药集团股份有限公司 一种甾体类肌松药注射液及其制备方法
US20230014293A1 (en) * 2021-07-02 2023-01-19 Fresenius Kabi Austria Gmbh Aqueous, room-temperature stable rocuronium composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8708886D0 (en) 1987-04-14 1987-05-20 Akzo Nv 2beta-morpholino-androstane derivatives
US5418226A (en) * 1992-04-22 1995-05-23 Akzo N.V. Monoquaternary 2,16-bispiperidinylandrostane derivatives
JP2925054B2 (ja) 1993-08-20 1999-07-26 宇部興産株式会社 疎水性物質の親水性化方法
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
WO1999027914A1 (fr) * 1997-11-27 1999-06-10 Akzo Nobel N.V. Formulation pharmaceutique de 2,16-bispiperidinylandrostane monoquaternaire pour administration par voie intramusculaire
US6911455B2 (en) * 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations
WO2007059019A2 (fr) 2005-11-14 2007-05-24 Winch Peter D Solutions colorees innovantes de medicaments injectables et de leurs sels pharmaceutiquement acceptables
CN101400369A (zh) * 2005-11-14 2009-04-01 P·D·温施 注射药物及其药学上可接受的盐的新颖的有色溶液
WO2007074641A1 (fr) * 2005-12-29 2007-07-05 Nipro Corporation Preparation pharmaceutique de solution aqueuse contenant un complexe de platine
RU2329799C1 (ru) * 2006-11-13 2008-07-27 Федеральное государственное учреждение Третий Центральный Военный Клинический госпиталь имени А.А. Вишневского Министерства обороны РФ Способ анестезии при проведении адреналэктомии по поводу феохромоцитомы надпочечника
WO2008065142A1 (fr) * 2006-11-29 2008-06-05 N.V. Organon Solution stabilisée de rocuronium comprenant un dérivé de l'éther sulfoalkylique de bêta-cyclodextrine
EP2647370B1 (fr) 2010-11-29 2019-02-27 Otsuka Pharmaceutical Factory, Inc. Préparation pour infusion

Also Published As

Publication number Publication date
WO2015001995A1 (fr) 2015-01-08
EP3017817A1 (fr) 2016-05-11
RU2016102844A (ru) 2017-08-04
EP3017817A4 (fr) 2017-03-22
NZ714485A (en) 2020-07-31
MX2015017549A (es) 2016-08-04
PT3017817T (pt) 2020-07-15
MX366310B (es) 2019-07-04
RU2680405C2 (ru) 2019-02-21
PH12015502850B1 (en) 2016-03-28
ES2794529T3 (es) 2020-11-18
IL243363A0 (en) 2016-02-29
DK3017817T3 (da) 2020-06-08
KR20160027976A (ko) 2016-03-10
CA2914154A1 (fr) 2015-01-08
JP5781698B2 (ja) 2015-09-24
CA2914154C (fr) 2021-05-25
BR112015030877B1 (pt) 2020-10-06
EP3017817B1 (fr) 2020-04-08
KR20170068624A (ko) 2017-06-19
AU2014285324A1 (en) 2015-12-17
SA515370275B1 (ar) 2021-06-10
AU2014285324B2 (en) 2019-05-23
CN105431151A (zh) 2016-03-23
US20160143919A1 (en) 2016-05-26
CN110251459A (zh) 2019-09-20
KR102060160B1 (ko) 2019-12-27
HK1224183A1 (zh) 2017-08-18
PH12015502850A1 (en) 2016-03-28
US10821119B2 (en) 2020-11-03
RU2016102844A3 (fr) 2018-05-14
IL243363B (en) 2019-05-30
JPWO2015001995A1 (ja) 2017-02-23
KR101803857B1 (ko) 2017-12-04

Similar Documents

Publication Publication Date Title
EP2970872A4 (fr) Micro-organismes et procédés de production d'oligosaccharides sialylés et à base de n-acétylglucosamine
EP2953012A4 (fr) Peau électronique, procédé de préparation et utilisation
EP2836270A4 (fr) Systèmes et procédés liés au traitement de la douleur dorsale
EP3058938A4 (fr) Composition de plante ayant des efficacités d'hydratation, anti-rides et anti-allergique, et son procédé de préparation
HK1225752A1 (zh) 含有發酵水果溶液的軟化組合物和其製備方法和用途
SG11201508347YA (en) Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes
HK1209671A1 (en) Aesthetic treatment device and method
EP3050437A4 (fr) Boisson au glucane et son procédé de préparation
PT3021881T (pt) Ácido hialurónico reticulado, processo para a sua preparação e sua utilização no campo da estética
EP3052078A4 (fr) Procédés et compositions permettant d'améliorer l'aspect de la peau
HK1219229A1 (zh) 用於疼痛緩解而不致麻木的組合物和方法
HRP20182199T1 (hr) Kruti pripravci koji sadrže tofogliflozin i postupak za njihovu proizvodnju
EP3066936A4 (fr) Composition épaississante et son procédé de production
EP3027049A4 (fr) Traitement de boissons visant à réduire les effets de constituants nocifs
IL245296A0 (en) Herbal composition, process for its preparation and use
EP2967406A4 (fr) Procédé et système pour calculer un qeeg
EP3079685A4 (fr) Composés de dérivé de sulfamate à utiliser dans le traitement ou l'atténuation de la douleur
IL243363B (en) A rocuronium preparation that causes less pain, and a method for its preparation
EP3080246A4 (fr) Compositions et procédés pour produire et gérer des adipocytes bruns
EP2960225A4 (fr) Nouvelle forme cristalline de 3,3',5,5'-tétraisopropyl-4,4'-diphénol et son procédé de fabrication
EP3079687A4 (fr) Composés dérivés de sulfamate destinés à être utilisés pour le traitement ou le soulagement de la douleur
EP3049123A4 (fr) Formulation de blocage de cathéter et son procédé de préparation
HK1197037A1 (en) Composition to be applied to the skin, and use thereof
GB2521356B (en) Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
IL229925A0 (en) A preparation for the treatment of baldness and a method for its production